Virum, Denmark

Nils Bruenner


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 1996-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nils Bruenner: Innovator in Antibody Research

Introduction

Nils Bruenner, an accomplished inventor based in Virum, Denmark, has made significant contributions to the field of antibody research. With two patents to his name, his work focuses on monoclonal and polyclonal antibodies targeting the urokinase plasminogen activator receptor (u-PAR). His innovative approaches show promise not only in basic research but also in potential therapeutic applications.

Latest Patents

Nils Bruenner's latest patents encompass the development of antibodies specifically directed against u-PAR. These antibodies have versatile applications: they can catch u-PAR in ELISA assays, facilitate detection in blotting, and be utilized in radioimmunoprecipitation assays to purify u-PAR in both intact and fragmented forms. Furthermore, they are crucial in immunohistochemical detection, particularly in the study of cancer cells at the invasive front. The patents also outline methods to inhibit the binding of pro-u-PA and active u-PA, effectively reducing cell surface plasminogen activation, which is critical in cancer metastasis and invasion.

Career Highlights

Over his career, Nils Bruenner has been associated with premier research organizations, including the Cancer Research Foundation of 1989, where his research has significantly contributed to advancements in cancer diagnostics and therapeutics. His developments are at the forefront of scientific inquiry, paving the way for new cancer treatment methodologies.

Collaborations

Throughout his career, Nils has collaborated with esteemed colleagues, including Niels Behrendt and Vincent Ellis. These partnerships have strengthened his research initiatives, fostering a collaborative environment aimed at tackling complex biomedical challenges through innovative antibody technologies.

Conclusion

Nils Bruenner’s work stands as a testament to the ongoing innovation within the field of antibody research. With his focused approach on u-PAR and its implications for cancer treatment, he continues to influence the scientific community and drive forward the development of novel therapeutic strategies. His patents not only highlight his inventive spirit but also emphasize the importance of collaboration in achieving breakthrough advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…